Neurodegenerative Disease Research - Proteomic Analysis Services
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH) intends to award a sole-source, firm-fixed price purchase order for Neurodegenerative Disease Research - Proteomic Analysis Services to Banner Sun Health. This acquisition, under NAICS 541380 (Testing Laboratories and Services), is for NULISA protein analysis services critical for Alzheimer's Disease/Related Dementias (AD/ADRD) research. The government plans to award within 90 days of this notice. Capabilities statements from other interested vendors are due within fifteen (15) days after publication (by May 28, 2026).
Scope of Work
The requirement is for NULISA (a novel proteomic liquid biopsy platform) testing services to identify biomarkers for AD/ADRD. Key services include:
- NULISA protein analysis.
- Support for longitudinal analytical consistency across assay runs, batches, and study periods.
- Assessment and correction of analytical drift.
- Normalization of datasets generated over time.
- Harmonization of current project data with future datasets and external collaborators.
Banner Sun Health is deemed uniquely qualified due to its existing, validated NULISA QC bridging cohort, which is essential for immediate project execution and data integrity without unacceptable delay or cost duplication.
Contract & Timeline
- Type: Notice of Intent (NOI) for a Sole-Source, Firm-Fixed Price Purchase Order.
- Period of Performance: One (1) twelve-month base period (8/1/2026 – 7/31/2027) and two (2) twelve-month option periods, extending through 7/31/2029.
- Place of Performance: Bethesda, MD.
- NAICS: 541380 - Testing Laboratories and Services (Size Standard: $19.0 Million).
- Published: May 13, 2026.
- Response Due: May 28, 2026 (15 days after publication).
Eligibility / Set-Aside
This is a sole-source acquisition under the authority of 41 U.S.C. 3304(a)(1) and FAR 6.302-1, citing "Only One Responsible Source." Full and open competition is not contemplated. Banner Health is identified as an "other than small business."
Submission & Evaluation
This is not a request for quotes. However, firms believing they can fully meet the requirement may submit a capabilities statement, including past performance, in writing to the identified points of contact within 15 days of publication. This documentation will be used solely to determine if the procurement can be conducted on a competitive basis. A determination not to compete remains at the Government's discretion.
Additional Notes
The NIH Intramural Center for Alzheimer's Disease and Related Dementias (CARD) requires these services to advance understanding, diagnosis, and treatment of AD/ADRD, with biomarkers being central to this mission.